• Explore /
  • Poster
  • / First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1<sup>+</sup> non–small cell lung cancer (NSCLC) or mesothelioma.

First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1+ non–small cell lung cancer (NSCLC) or mesothelioma.

Abstract Poster

Authors

null

Hongyun Zhao

State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Hongyun Zhao , Jianhua Chen , Zhengbo Song , Yanqiu Zhao , Yubiao Guo , Gang Wu , Yuxiang Ma , Wenwei Zhou , Xiaoqing Yu , Fangfang Gao , Yugang Dong , Ruiguang Zhang , Chen Yang , Xiaohong Tian , Hengbang Wang , Yanhua Tu , Juan Yu , Xuemei Sun , Li Zhang , Yifan Zhai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03917043

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9071)

DOI

10.1200/JCO.2022.40.16_suppl.9071

Abstract #

9071

Poster Bd #

58

Abstract Disclosures

Similar Posters

First Author: Yuxiang Ma

First Author: Yuxiang Ma

First Author: Caicun Zhou

First Author: Benjamin Besse